Clinical-stage precision medicine company EXACT Therapeutics AS (Euronext Growth Oslo:EXTX) announced on Wednesday that it has been granted a patent in the UK covering its proprietary Acoustic Cluster Therapy (ACT) platform for non-invasive drug delivery to the central nervous system.

UK Patent no. 2104590.1 protects ACT's use in treating brain-related diseases, including glioblastoma, by overcoming the challenges of the blood-brain barrier. This marks the first territory approval for this patent, representing a key milestone in the development of EXACT's central nervous system (CNS) pipeline.

ACT leverages ultrasound technology to enhance targeted delivery of pharmaceuticals, potentially expanding therapeutic access to larger brain areas.

EXACT recently reported promising non-clinical results in glioblastoma, highlighting ACT's potential as a novel approach in neuro-oncology.

The company continues to advance ACT as part of its broader precision medicine strategy in oncology.